2018 Alzheimer’s Disease Research Summit

Due to inclement weather in the Washington, DC area on March 2, the second day of the 2018 NIH AD Research Summit Program was cancelled. We are delighted to announce that we will bring the Day 2 Summit speakers together on the NIH Campus on May 24 and host the Day 2 Summit Program as a live videocast event. The videocast registration is available here.

 

The National Institutes of Health (NIH) is convening the 3rd Alzheimer’s Disease (AD) Research Summit to be held on March 1-2, 2018 in Bethesda, Maryland. The program will build on the foundation laid by the 2012 and 2015 NIH AD Research Summits and the U.S. National Alzheimer’s Project Act (NAPA)/National Plan to Address AD.

The Summit’s central goal is to continue the development of an integrated multidisciplinary research agenda necessary to address critical knowledge gaps and accelerate the discovery and delivery of efficacious treatments for AD patients at all stages of disease. Key to achieving this goal is the identification of resources, infrastructure and multi-stakeholder partnerships necessary to successfully implement this research agenda and strategies to empower patients and engage citizens.

The 2018 Summit will bring together leading researchers, innovators and public advocates from academia, industry, the not-for-profit sector and NIH. The program will feature progress made toward achieving the National Plan’s research goal to Treat and Prevent Alzheimer’s by 2025, as well as a robust discussion on the continued transformation of the process of AD research and drug development into one that is participatory, collaborative, well-integrated and capable of delivering the cures that are so desperately needed.

 

Goals

  • Measure the progress made towards achieving the National Plan’s research goal to Treat and Prevent Alzheimer’s Disease by 2025.
  • Continue the development of an integrated multidisciplinary research agenda necessary to address critical knowledge gaps and accelerate the discovery and delivery of efficacious treatments for AD patients at all stages of disease.
  • Identify resources, infrastructure and multi-stakeholder partnerships necessary to successfully implement this research agenda and strategies to empower patients and engage citizens.

Partners

AbbVie Inc.
Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD)
Alzheimer’s Association
Biogen
Genentech
GHR Foundation
The Rosalinde and Arthur Gilbert Foundation
Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.
National Institute on Aging (NIA)
The Shiley Foundaton
UsAgainstAlzheimer’s

Contacts

Development office at development@fnih.org.